Artelo Biosciences, Inc.

Artelo Biosciences, Inc. (ARTL) is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system, for conditions like cancer-related anorexia, chemotherapy-induced peripheral neuropathy (CIPN), and others. Key pipeline includes ART27.13, a dual CB1/CB2 agonist in Phase 1b/2a CAReS trial showing interim 6.38% mean weight gain vs. -5.42% placebo loss; ART26.12, FABP5 inhibitor with Phase 1 completed in 2025 demonstrating safety; and ART12.11, CBD cocrystal with enhanced pharmacokinetics. Incorporated in Nevada in 2011, headquartered in Solana Beach, California, the company is a smaller reporting company with 736,127 shares outstanding as of March 18, 2026, post 1-for-3 reverse split effective March 10, 2026. Financial position as of December 31, 2025: cash and equivalents $600 thousand, total current liabilities $4,044 thousand, stockholders' deficit $(1,272) thousand, accumulated deficit $(63,015) thousand. This S-1/A registers a best-efforts public offering of 1,641,587 shares of common stock (or pre-funded warrants) at $7.31 per share, with Placement Agent Warrants for 131,327 shares; estimated max net proceeds $10.8 million after 8% fees to Craft Capital Management LLC and expenses, for working capital and general corporate purposes. No minimum required, proceeds highly variable. The offering addresses low cash runway, Nasdaq equity compliance extension to March 30, 2026, and recent $310K bridge notes, funding clinical advancement amid delisting risks and dilution.

Key Takeaways